Saman Ghahremani, MD
Ophthalmology · Silver Spring, MDNPI 1326092958
Payments from drug & device makers
Across 113 payments — averaging $39.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lumenis BE Inc$2K
- Biotissue Holdings Inc.$477
- AbbVie$379
- Sun Pharmaceutical Industries Inc.$275
- Bausch & Lomb, A Division Of Bausch Health US, LLC$193
- Mallinckrodt Hospital Products Inc.$181
- plus $1K from 19 others
What the payments were for
- Food & beverage$4,484100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lumenis BE Inc | 1 | $1,968 |
| Biotissue Holdings Inc. | 12 | $477 |
| AbbVie(2 entities) | 17 | $379 |
| Sun Pharmaceutical Industries Inc. | 17 | $275 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 11 | $193 |
| Mallinckrodt Hospital Products Inc. | 7 | $181 |
| Tarsus Pharmaceuticals, Inc. | 5 | $135 |
| Novartis | 6 | $121 |
| Bausch & Lomb Americas Inc. | 6 | $117 |
| Oyster Point Pharma, Inc. | 6 | $114 |
| Alcon | 3 | $108 |
| Dompe US, Inc. | 3 | $70 |
| Aerie Pharmaceuticals, Inc. | 3 | $49 |
| Revance Therapeutics, Inc. | 2 | $44 |
| Eyevance Pharmaceuticals LLC | 3 | $43 |
| Shire North American Group Inc | 2 | $37 |
| Rxsight Inc | 1 | $23 |
| Sanofi | 1 | $22 |
| Sight Sciences, Inc. | 1 | $21 |
| Kala Pharmaceuticals, Inc. | 1 | $21 |
| Lumibird Medical Inc. | 1 | $20 |
| Thea Pharma Inc. | 1 | $19 |
| Spark Therapeutics, Inc. | 1 | $19 |
| Harrow Eye, LLC | 1 | $14 |
| Johnson & Johnson Vision Care, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- optilight$1,968
- Prokera$210
- AmnioGraft$210
How this compares
$4,484 in reported general payments places this provider in the 75th percentile of 493 ophthalmology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 133 | $208,757 |
| LumiganBimatoprost | 266 | $177,381 |
| RestasisCyclosporine | 87 | $140,666 |
| Cyclosporine | 78 | $42,031 |
| RhopressaNetarsudil Mesylate | 34 | $26,216 |
| CombiganBrimonidine Tartrate/Timolol | 54 | $22,183 |
| XdemvyLotilaner | 12 | $22,158 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 111 | $19,033 |
| Travoprost | 78 | $17,061 |
| Alphagan PBrimonidine Tartrate | 40 | $14,289 |
| VyzultaLatanoprostene Bunod | 17 | $11,671 |
| MieboPerfluorohexyloctane/Pf | 15 | $11,302 |
| ProlensaBromfenac Sodium | 30 | $10,393 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 39 | $9,416 |
| Loteprednol Etabonate | 50 | $7,589 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $379 | $354,519447 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $117 | $231,730165 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $49 | $32,00549 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate, Alrex | $193 | $24,07899 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $135 | $22,15812 claims |
| AlconSimbrinza | $108 | $9,41639 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 493 ophthalmology providers in Maryland.
Other ophthalmology in Silver Spring
- Allen HuHagerstown$47.9M
- David WarrowHagerstown$10M
- Daniel FinkelsteinBaltimore$6.9M
- Eric SuanBaltimore$6.9M
- Peter CampochiaroBaltimore$5.4M
- Neil BresslerBaltimore$3.6M
- Alfred SommerBaltimore$2.9M
- Richard AdlerBaltimore$2.7M
- John ThompsonBaltimore$1.8M
- Peter McDonnellBaltimore$1.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.